Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study

BACKGROUND: To compare the efficacy and safety of pyrotinib and trastuzumab emtansine (T-DM1) in patients who experienced disease progression on trastuzumab and lapatinib treatment. METHODS: This was a real-world study that included cases of metastatic breast cancer (MBC) with trastuzumab and lapati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Feng, Xu, Fengrui, Li, Jianbin, Wang, Tao, Bian, Li, Zhang, Shaohua, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867920/
https://www.ncbi.nlm.nih.gov/pubmed/33569405
http://dx.doi.org/10.21037/atm-20-4054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867920/
https://www.ncbi.nlm.nih.gov/pubmed/33569405
http://dx.doi.org/10.21037/atm-20-4054

Ejemplares similares